- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01029067
Metacognitive Training in Schizophrenia (MCT)
March 2, 2015 updated by: Universitätsklinikum Hamburg-Eppendorf
Metacognitive Training (MCT) Compared With Cognitive Remediation (CR) in Schizophrenia: a Randomized Controlled Study Over 4 Weeks
Over a period of 4 weeks, metacognitive training for schizophrenia patients (MCT), delivered both in a group and individually, is compared to cognitive remediation (CogPack training).
Blind to treatment assignment, both groups are assessed before intervention and four weeks later with the Positive and Negative Symptoms Scale (PANSS), the Psychosis Rating Scales (PSYRATS) and cognitive tests.
Delusion severity serves as the primary endpoint.
It is assumed that MCT will improve delusion severity to a greater extent than CR in the course of 4 weeks taking medication into account.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Metacognitive training for schizophrenia patients (MCT) is a manualized group intervention that can be obtained cost-free online.
MCT seeks to sharpen the awareness of schizophrenia spectrum patients on cognitive biases (e.g.
jumping to conclusions) contributing to delusion formation and maintenance and conveys cognitive strategies to counter these.
The present trial combines group MCT with an individualized cognitive-behavioral oriented approach entitled MCT+.
Patients with schizophrenia are randomly allocated to either metacognitive treatment (MCT) or cognitive remediation (CogPack training).
Blind to treatment assignment, both groups are assessed prior to intervention and four weeks later with the Positive and Negative Symptoms Scale (PANSS), the Psychosis Rating Scales (PSYRATS) and cognitive tasks.
Delusion scores derived from the PANSS and PSYRATS serve as main outcome parameters.
We also explore if MCT improves jumping to conclusions with a probabilistic reasoning task.
To make results as generalizable as possible to a typical inpatient population, broad inclusion criteria are chosen.
Patients are only excluded if age is < 18 and > 65 years and diagnoses do not meet criteria of a schizophrenia spectrum disorder.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hamburg, Germany, 20246
- University Medical Center Hamburg Eppendorf
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 61 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- schizophrenia spectrum disorder
Exclusion Criteria:
- intellectual disability (IQ < 70)
- unable to provide informed consent
- hostility on PANSS > 4
- suspiciousness on PANSS > 5
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Cognitive Remediation
Computerized cognitive remediation (CogPack training).
A fixed series is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed.
The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises.
At the end of each session, the patient receives individual feedback on his or her performance.
To match with group MCT, eight sessions are administered.
Each session lasts approximately 45-60 minutes.
|
Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
|
|
Experimental: Metacognitive Training
The group metacognitive training program (MCT) is fully documented (Moritz, Woodward, & Metacognition Study Group, 2007; VanHam Campus Press) and can be obtained in more than 15 languages cost-free via the following link: www.uke.de/mkt.
The group program is delivered to groups of 3-10 patients by trained psychologists addressing delusion-related metacognitive biases (e.g., jumping to conclusions).
The eight modules are presented via a video projector using pdf-converted Power-Point slides.
Each group session lasts approximately 45-60 minutes.
Individualized MCT (MCT+) follows group sessions and accords to the general guidelines for cognitive-behavioral therapy.
For each patient, 8 one-to-one sessions were carried in addition to one session relating to the medical history.
|
Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
delusion severity as assessed with the Positive and Negative Syndrome Scale (PANSS); sum of item scores p1, p5, p6 and g9
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Steffen Moritz, PhD, Universitätsklinikum Hamburg-Eppendorf
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
December 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
December 5, 2009
First Submitted That Met QC Criteria
December 8, 2009
First Posted (Estimate)
December 9, 2009
Study Record Updates
Last Update Posted (Estimate)
March 3, 2015
Last Update Submitted That Met QC Criteria
March 2, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
First Affiliated Hospital of Fujian Medical UniversityNot yet recruiting
-
Fundació Institut de Recerca de l'Hospital de la...Recruiting
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Newron Pharmaceuticals SPARecruitingTreatment-resistant SchizophreniaUnited States, India
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarCompletedTreatment Resistant SchizophreniaIndia
-
Shanghai Zhongze Therapeutics Co., Ltd.Yale UniversityNot yet recruiting
-
Ole Köhler-ForsbergAarhus University HospitalRecruiting
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Recruiting
Clinical Trials on Cognitive Remediation
-
Queen's UniversityCompleted
-
Queen's UniversityPfizerCompleted
-
Yale UniversityCompletedCancer | Cancer of the ProstateUnited States
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
VA Office of Research and DevelopmentCompleted
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH); Columbia UniversitySuspendedSchizophrenia | Schizoaffective DisorderUnited States
-
Queen's UniversityCompleted
-
University of GroningenLentis Psychiatric Institute; GGZ Friesland; Stichting CosisRecruitingSevere Mental IllnessNetherlands
-
Douglas Mental Health University InstituteMcGill University; Canadian Institutes of Health Research (CIHR)Recruiting
-
Gemma Garrido GarcíaCompleted